Microbiome Diagnostics Market Growth Accelerates as Feces and Saliva Emerge as Dominant Sample Types in Advanced Diagnostic Applications

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Microbiome Diagnostics Market - (By Product (Reagents & Kits, Instruments), By Technology (16S rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics, Other Technology), By Sample (Feces, Saliva, Skin, Other Sample), By Application (Disease Diagnostics Application (Gastrointestinal Disorders, Metabolic Diseases, Other Application), Research Application), By End-User (Hospitals, Academic and Research Institutes, Biotechnology and Pharmaceutical Companies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Microbiome Diagnostics Market is valued at US$ 154.9 Mn in 2023, and it is expected to reach US$ 488.2 Mn by 2031, with a CAGR of 15.6% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2398

Microbiome diagnostics refers to the assessment of microbial communities residing in and on the human body to detect alterations associated with specific diseases, health disorders, or general physiological conditions. The human microbiome-comprising bacteria, viruses, fungi, and other microorganisms-plays an essential role in key biological processes, including digestion, immune regulation, and neurological function. Technological advancements and improved bioinformatics capabilities have substantially enhanced the precision and depth of microbiome analysis.

These innovations have enabled the development of advanced diagnostic tools applicable to infectious disease monitoring, personalized treatment strategies, and gastrointestinal health management. Market growth is further supported by rising investment in microbiome-focused research and expanding partnerships between academic institutions and biotechnology firms. However, the sector continues to face challenges, particularly in navigating regulatory requirements and establishing standardized testing protocols, both of which influence the pace and direction of industry advancement.

List of Prominent Players in the Microbiome Diagnostics Market:
• Yakult Honsha Co.
• AOBiome
• Enterome Biosciences SA
• Microbiome Therapeutics LLC
• Osel, Inc.
• Rebiotix, Inc.
• Second Genome
• Seres Therapeutics
• Synthetic Biologics, Inc.
• Vedanta Biosciences
• 4D Pharma
• Du Pont De Nemours and Co.
• Ferring Pharmaceuticals
• Genetic Analysis AS
• Atlas Biomed
• Biome Oxford Ltd.
• Illumina Inc.
• Microba Life Sciences
• Dna Genotek (Orasure Technologies, Inc.)
• Viome Life Sciences
• Sun Genomics
• Becton, Dickinson And Company
• Daytwo
• OraSure Technologies, Inc.
• Other Market Players

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
Expanding research initiatives and educational programs focused on the human microbiome are key factors propelling the microbiome diagnostics market. Collaborative efforts between academic institutions and industry participants are accelerating the development of advanced diagnostic platforms and broadening scientific understanding of the microbiome's impact on human health. These partnerships are enabling the conversion of foundational research into clinically relevant solutions, thereby creating new opportunities for microbiome-based diagnostics.

As scientific knowledge deepens, demand for specialized diagnostic tools continues to rise. Additionally, awareness campaigns targeted at healthcare professionals and consumers are facilitating the adoption of personalized, microbiome-driven diagnostic approaches, contributing to improved patient care and supporting overall market growth. The increasing emphasis on preventive health and wellness is further stimulating market expansion.

Challenges:
The market faces substantial cost-related challenges, particularly associated with high production and processing expenses. The complexity of manufacturing processes-such as compression molding and continuous lamination-significantly increases the overall cost structure. Limited access to essential raw materials adds to these financial pressures. Moreover, the high investment required for research and development, combined with inadequate infrastructure and gaps in comprehensive microbiome datasets, continues to hinder market advancement. Despite funding initiatives from both governmental and private organizations, many research and academic institutions still encounter budgetary limitations, restricting their ability to adopt sophisticated and often costly diagnostic technologies.

Regional Trends:
North America is expected to maintain a leading position in the microbiome diagnostics market, supported by an advanced healthcare system, strong technological capabilities, and the presence of major industry participants. The region benefits from consistent demand, a favorable innovation landscape, and supportive economic conditions. While developed markets continue to advance through well-established research networks and export-oriented strategies, emerging regions are experiencing growing demand for innovative diagnostic solutions driven by expanding healthcare access and increased interest in personalized medicine.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2398

Recent Developments
• In July 2022, OraSure Technologies, Inc. has made its OMNIgene®•GUT DNA and RNA product (OMR-205) available to researchers studying the gut microbiota. OraSure technology is a prominent worldwide frontrunner in the field of point-of-care and home diagnostic testing, as well as sample collecting technology. The product facilitated the collection, preservation, storage, and transfer of microbial DNA and RNA at room temperature for the purpose of analyzing the gut microbiome. The product was manufactured by DNA Genotek, a subsidiary of OraSure.
• In Aug 2021, A partnership between Second Genome and Arena Pharmaceuticals to identify gastrointestinal biomarkers was recently disclosed. A proof-of-concept study utilizing microbiome signals was conducted by Second Genome as part of Arena's CULTIVATE Phase 2/3 clinical trial for Crohn's disease.

Market Segmentation-
By Product-
• Reagents & Kits
• Instruments
By Technology-
• 16S rRNA Sequencing
• Shot Gun Metagenomics
• Metatranscriptomics
• Other Technology
By Sample-
• Feces
• Saliva
• Skin
• Other Sample
By Application-
• Disease Diagnostics Application
o Gastrointestinal Disorders
o Metabolic Diseases
o Other Application
• Research Application
By End-User-
• Hospitals
• Academic and Research Institutes
• Biotechnology and Pharmaceutical Companies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/microbiome-diagnostics-market/2398

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.